Market Research Logo
Region: Africa
Category: Country Overviews

Africa Country Overviews

(80 reports matching your criteria)
  • Cote d'Ivoire Pharmaceuticals & Healthcare Q4 2018

    ... advantage, key factors such as limited access tomedicines and a lack of healthcare infrastructure will limit commercial opportunities. We hold a more positive long-term outlook onthe back of economic prosperity and the push for healthcare ... Read More

  • Kenya Pharmaceuticals & Healthcare Q4 2018

    ... ‘Big Four Agenda’ to 2022, providing upside risks to ourpharmaceuticals and healthcare forecasts. However, while this development highlights greater political will to improve healthcareaccess in Kenya, the target is highly ambitious over the coming five ... Read More

  • Zimbabwe Pharmaceuticals & Healthcare Q3 2018

    ... profile, wherea high prevalence of HIV/AIDS contributes to short life expectancy and low non-communicable disease burden. This profile willbenefit generic drugmakers operating in the country over the long-term, especially as the population grows. However, Zimbabwe ... Read More

  • Botswana Pharmaceuticals & Healthcare Q3 2018

    ... by a weakregulatory environment, small pensionable population and a highly ruralised community. Generic medicines will continue todominate the market, with patented drugmakers choosing to operate in larger markets in the region such as South African. Read More

  • Gabon Pharmaceuticals & Healthcare Q3 2018

    ... diseases will remain significant, we expect the increasein the incidence of non-communicable diseases to be the key driver of longer-term pharmaceutical market's trajectory. Commercialopportunities will mostly remain in the generic segment, given the rising role ... Read More

  • Sub-Saharan Africa Pharmaceuticals & Healthcare Q3 2018

    ... procedures, a lack of enforced patent laws, and ageneral lack of transparency that ensures the region lags behind others globally for revenue-earning opportunities. Despite this, theregion's pharmaceutical markets will continue to provide long-term opportunities for ... Read More

  • Tunisia Pharmaceuticals & Healthcare Q3 2018

    ... expect it to retain this position over the long term. Highlighting themarket's longer-term potential, some multinational drugmakers have shown their willingness to do business in the country, thoughthe majority choose to operate indirectly to minimise ... Read More

  • Ethiopia Pharmaceuticals & Healthcare Q3 2018

    ... multinational drugmakers will remaindecidedly difficult to exploit as the lack of intellectual property protection, weak healthcare system, and abundance of povertyremain entrenched. Ethiopia certainly has the potential to improve its pharmaceutical manufacturing base, largely supported ... Read More

  • Ghana Pharmaceuticals & Healthcare Q3 2018

    ... the market, somewhat limiting high-value commercial opportunities. We believethat Ghana’s ambition of becoming the strategic hub for pharmaceutical investment in the ECOWAS region as a highly ambitioustarget, with Nigeria’s dominance as the primary medicine manufacturer ... Read More

  • Namibia Pharmaceuticals & Healthcare Q3 2018

    Namibia Pharmaceuticals & Healthcare Q3 2018 BMI View: The small overall size of the market will continue to discourage more concerted efforts by multinationals to enter Read More

  • Mozambique Pharmaceuticals & Healthcare Q3 2018

    ... – and poor regulatory enforcement. Although agrowing population, high disease burden and some efforts by the government to improve overall healthcare will support demandfor generic medicines, albeit limited, Mozambique will remain one of the least ... Read More

  • Nigeria Pharmaceuticals & Healthcare Q3 2018

    ... in line with increasinggovernment support, although the benefits are unlikely to be realised over the near-term. The majority of multinational drugmakerswill continue to opt for an indirect presence as the business climate remains decidedly difficult ... Read More

  • Tanzania Pharmaceuticals & Healthcare Q3 2018

    ... healthcare system and lowlevels of affordability. However, we forecast the pharmaceutical market to expand rapidly over the coming years, albeit from a smallbase compared to developed markets, spurred on by a rapidly growing population and ... Read More

  • Mauritius Pharmaceuticals & Healthcare Q3 2018

    ... Healthcare infrastructureexpansion and the rising burden of chronic diseases will ensure that demand for treatment remains high. Despite short-termeconomic headwinds, Mauritius’s long-term growth outlook is broadly positive, as the island is moving towards becoming atranshipment ... Read More

  • Cameroon Pharmaceuticals & Healthcare Q3 2018

    ... rolling out of this health financing mechanism will proceed at a slowpace, however, given the current low level of health system development. More broadly, sustained economic growth bodes well forpharmaceutical spending growth over the medium ... Read More

  • Angola Pharmaceuticals & Healthcare Report Q3 2018

    ... demographic, per capita spending on medicines will remainsignificantly low over our forecast period. However, overall growth of the market will be supported by a rapidly growing populationcoupled with small but steady improvements to healthcare access ... Read More

  • Zambia Pharmaceuticals & Healthcare Report Q3 2018

    ... However, few opportunities exist from the perspective ofmultinational companies, given factors such as the low purchasing power and the wide-spread presence of counterfeit medicines.On the other hand, authorities' support for the reduction of reliance on ... Read More

  • Algeria Pharmaceuticals & Healthcare Report Q3 2018

    ... years. Algeria’s strategic geographicalposition and government incentives for investors will support the country’s long-term aspiration towards becoming a drugmanufacturing and export base. That said, slow progress in revising drug pricing regulations and import restrictions will ... Read More

  • Zimbabwe Pharmaceuticals & Healthcare Q2 2018

    ... thepublic healthcare sector received only minor contributions from the government, partly a result of growing public debt. Followingthe successful replacement of Mugabe with the more reform-minded President Emmerson Mnangagwa in late 2017, we hold amore ... Read More

  • Tanzania Pharmaceuticals & Healthcare Report Q2 2018

    ... over the coming years. However, we note that growth will bepartly due to inflationary pressures from a relatively low value base. The demand for high-value drugs will remain limited by itsunderdeveloped healthcare system and low ... Read More

  • Cameroon Pharmaceuticals & Healthcare Report Q2 2018

    ... implementation phase reach a high level ofsuccess, the UHC scheme has the potential to transform Cameroon's health system while positioning the country among the mostpromising in Sub-Saharan Africa in terms of health sector growth. We ... Read More

  • Middle East And North Africa Pharmaceuticals & Healthcare Report Q2 2018

    ... urbanization, the region's overwhelming chronic disease burdenwill be an important factor supporting pharmaceutical and healthcare market growth over a multi-year horizon. There is a significantdisparity between different countries' healthcare systems in the MENA region, resulting ... Read More

  • Uganda Pharmaceuticals & Healthcare Report Q2 2018

    ... access tothese essential medicines. While the government recognises the need to improve the situation and is implementing certainstrategies to address this, health sector inefficiencies persist and there is an absence of a sustainable, long-term plan. Read More

  • Cote d'Ivoire Pharmaceuticals & Healthcare Report Q2 2018

    ... of healthcare coverage deter any meaningful investment bymultinational firms. While a positive economic trajectory bodes well for government finances, the focus will remain on the deliveryof basic healthcare services, offering limited opportunities for foreign pharmaceutical ... Read More

  • Morocco Pharmaceuticals & Healthcare Report Q2 2018

    ... improving healthcare quality and coverage. However, innovative drugmakers willremain deterred by the relatively small scale of the market as well as the low purchasing power of the population. Further downsiderisks include the government's increasing preference ... Read More

< prev 1 3 4